Soft tissue sarcoma · 9 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Epirubicin and Ifosfamide Variant #03 | — | R 27 105 | 21d | — | — | — | — | — |
Doxorubicin, Ifosfamide, RT Variant #01 | — | R 17 759 | 21d | — | — | — | — | — |
MAID Variant #01 | — | R 14 399 | 21d | — | — | — | — | — |
Docetaxel and Gemcitabine Variant #01 | — | R 4 912 | 21d | ~6.2 mo | — | ~9 | ~R 44 207 PFS proxy · indirect | 1 |
Dacarbazine and Gemcitabine Variant #01 | — | R 3 790 | 14d | — | ~16.8 mo | — | — | 1 |
Gemcitabine and Vinorelbine Variant #01 | — | R 3 329 | 21d | — | ~6.7 mo | — | — | 2 |
Dacarbazine and Doxorubicin Variant #01 | — | R 1 191 | 21d | — | — | — | — | — |
Doxorubicin and Olaratumab Variant #01 Partial | — | R 718 | 21d | — | ~20.4 mo | — | — | 1 |
Doxorubicin and Ifosfamide N/A - secondary systemic drug | — | R 177 | 21d | — | — | — | — | — |
9 of 9 regimens shown